Zimbabwe has turned down a major US health deal worth $367m (272 million pounds) over five years because of the United States' insistence on confidential data.
The decision became public following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesperson later stated that the United States was seeking genetic material for scientific study and commercial purposes while was unwilling to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more talks to reach a deal agreeable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Implications
This rejection comes after a similar situation in Kenya, where a court suspended a related deal with the US following concerns were raised about the security of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost transparency and responsibility.
According to reports, 16 nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information over an extended period, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," he stated.
"Effectively, our country would provide the raw materials for medical research with no certainty that the final treatments would be available to our population should a new disease outbreak emerge."
National Interest and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining systems already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how future collaboration could be designed in a way that respects the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but recommended that negotiations need to persist considering much of the country's Aids initiatives relied on external financing.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can frequently be resolved through technical clarification and negotiated safeguards," the group said.
The halted deal emphasises the ongoing challenges between receiving crucial international aid and protecting a country's data in an ever more interconnected world.